BRIDGEBIO PHARMA INC.

BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

02 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines

18 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

10 Jan 2024 16:15:42 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

10 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

03 Jan 2024 15:30:00 By Nasdaq GlobeNewswire

BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)

03 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

13 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

08 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

05 Dec 2023 06:45:07 By Nasdaq GlobeNewswire

BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023

09 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

08 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update

02 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

10 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

09 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments

03 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces $250 Million Private Placement Equity Financing

25 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

08 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

06 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023

27 Aug 2023 05:15:00 By Nasdaq GlobeNewswire